← Browse by Condition
Medical Condition

neoadjuvant chemoimmunotherapy

Total Trials
4
Recruiting Now
4
Trial Phases
Phase 1, Phase 2, Phase 2, Phase 2, Phase 3

ClinicalMetric tracks all active clinical trials for neoadjuvant chemoimmunotherapy sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — neoadjuvant chemoimmunotherapy Clinical Trials

How many clinical trials are currently recruiting for neoadjuvant chemoimmunotherapy?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for neoadjuvant chemoimmunotherapy, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for neoadjuvant chemoimmunotherapy?
neoadjuvant chemoimmunotherapy research spans Phase 1 (1 trial), Phase 2 (3 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a neoadjuvant chemoimmunotherapy clinical trial?
Eligibility criteria for neoadjuvant chemoimmunotherapy trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Phase 2
3
Phase 3
1
Top Sponsors
Tongji Hospital 2 trials
University Hospital, Antwerp 1 trial
Shanghai Zhongshan Hospital 1 trial

Recruiting Clinical Trials

NCT07121374 Phase 1, Phase 2
Recruiting
NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility Study
Enrollment
37 pts
Location
Belgium
Sponsor
University Hospital, Antwerp
View Trial →
NCT06289062 Phase 2
Recruiting
Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer
Enrollment
40 pts
Location
China
Sponsor
Tongji Hospital
View Trial →
NCT06288373 Phase 2, Phase 3
Recruiting
Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC
Enrollment
440 pts
Location
China
Sponsor
Tongji Hospital
View Trial →
NCT05740995
Recruiting
Neoadjuvant Anti-PD-1 Plus Chemotherapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
Enrollment
40 pts
Location
China
Sponsor
Shanghai Zhongshan Hospital
View Trial →

Related Conditions

cervical cancer (2) pleural epithelioid mesothelioma (1) mesothelioma pleura (1) fertility preservation (1) locally advanced cervical cancer (1) concurrent chemoradiotherapy (1) esophageal squamous cell carcinoma (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology